Ian Sanne to CD4 Lymphocyte Count
This is a "connection" page, showing publications Ian Sanne has written about CD4 Lymphocyte Count.
Connection Strength
2,384
-
Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
Score: 0,120
-
Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
Score: 0,100
-
Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. 2014 Dec; 19(12):1411-9.
Score: 0,099
-
CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc. 2014; 17:19139.
Score: 0,099
-
Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17:18651.
Score: 0,095
-
Tenofovir use and pregnancy among women initiating HAART. AIDS. 2012 Nov 28; 26(18):2393-7.
Score: 0,088
-
Treatment outcomes after 7 years of public-sector HIV treatment. AIDS. 2012 Sep 10; 26(14):1823-8.
Score: 0,086
-
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med. 2012; 9(4):e1001207.
Score: 0,084
-
Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
Score: 0,083
-
Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
Score: 0,083
-
Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar; 113(3):362-72.
Score: 0,083
-
Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
Score: 0,078
-
High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
Score: 0,073
-
The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010 Mar 27; 24(6):915-9.
Score: 0,073
-
Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
Score: 0,068
-
Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol. 2009 Jan-Feb; 53(1):10-7.
Score: 0,067
-
Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S40-51.
Score: 0,062
-
Deciding when to institute terminal palliative care for AIDS patients--an evidence-based approach. S Afr Med J. 2001 Jul; 91(7):559-60.
Score: 0,040
-
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? Int J Infect Dis. 2001; 5(1):43-8.
Score: 0,038
-
Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
Score: 0,035
-
Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting. J Clin Microbiol. 2018 12; 56(12).
Score: 0,033
-
Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
Score: 0,032
-
Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
Score: 0,030
-
Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS. 2017 Jul 17; 31(11):1611-1619.
Score: 0,030
-
Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
Score: 0,029
-
Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
Score: 0,028
-
Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016 May; 13(5):e1002015.
Score: 0,028
-
The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. PLoS One. 2016; 11(2):e0148546.
Score: 0,027
-
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
Score: 0,027
-
Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):323-8.
Score: 0,027
-
Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
Score: 0,026
-
The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
Score: 0,026
-
Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
Score: 0,024
-
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8.
Score: 0,024
-
Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
Score: 0,024
-
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014 Apr; 14(4):281-90.
Score: 0,024
-
Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay. BMJ Case Rep. 2013 Aug 28; 2013.
Score: 0,023
-
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
Score: 0,023
-
Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
Score: 0,022
-
The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
Score: 0,022
-
Loss to follow-up before and after delivery among women testing HIV positive during pregnancy in Johannesburg, South Africa. Trop Med Int Health. 2013 Apr; 18(4):451-60.
Score: 0,022
-
Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e39-46.
Score: 0,022
-
Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
Score: 0,021
-
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
Score: 0,020
-
Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
Score: 0,020
-
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
Score: 0,020
-
Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
Score: 0,020
-
Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
Score: 0,020
-
Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
Score: 0,019
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
Score: 0,019
-
Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:43-7.
Score: 0,018
-
Lost opportunities to complete CD4+ lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ. 2010 Sep 01; 88(9):675-80.
Score: 0,018
-
Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. Cancer Causes Control. 2010 Mar; 21(3):433-43.
Score: 0,018
-
CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort. Cytometry B Clin Cytom. 2008; 74 Suppl 1:S131-40.
Score: 0,016
-
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
Score: 0,012
-
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
Score: 0,012